您是第 11113493 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

NCI-H358人非小细胞肺癌细胞 (STR鉴定)

英文名:NCI-H358
货号:ZQ0384
价格:¥1350.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

NCI-H358人非小细胞肺癌细胞 (STR鉴定)

¥1350.00
+

NCI-H358人非小细胞肺癌细胞专用培养基

¥350.00 ¥480.00

配套完培,组合使用,省时省力!

=

细胞套餐惊爆价

¥1700 ¥2080.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

NCI-H358人非小细胞肺癌细胞

货号

ZQ0384

产品介绍

NCI-H358,也被称为H-358或NCIH358,是一种上皮样细胞系,来源于一名非小细胞肺癌(NSCLC)亚型细支气管肺泡癌患者。超微结构研究表明细胞质中有Clara细胞的特征结构 细胞表达主要的肺表面结合蛋白SP-A的蛋白和RNA。 不表达SP-B和SP-C。 他们在软琼脂中的克隆形成效率为0.83%。NCI-H358细胞在以非小细胞肺癌为重点的癌症研究中尤其重要,特别是在探索肺腺癌的生物学和治疗方面。
该细胞系对于研究靶向表皮生长因子受体(EGFR)治疗的有效性至关重要,因为EGFR突变是治疗非小细胞肺癌的一个重要焦点。此外,NCI-H358细胞对于研究KRAS突变的作用很有价值,KRAS突变在肺癌中很普遍,并且已知会驱动致癌活性。NCI-H358细胞中这些突变的研究有助于阐明参与肺癌进展和治疗耐药的分子途径。
NCI-H358细胞系含有p53的纯合缺失,p53是一种主要的肿瘤抑制因子。H358肺癌细胞系也被用于评估新的治疗方法的潜力,例如针对特定致癌途径的SOS1 PROTACs。
总之,来自细支气管肺泡癌的NCI-H358细胞系是研究非小细胞肺癌的重要工具。这对于研究egfr靶向治疗和KRAS突变在肺癌中的作用具有重要意义。它在癌症研究中的应用扩展到旨在减轻致癌突变影响和改善肺癌患者预后的新治疗策略的开发。

种属

性别/年龄

组织

肺/支气管;来源于转移部位:肺泡

疾病

细支气管肺泡癌;非小细胞肺癌

细胞类型

肿瘤细胞 

形态学

上皮细胞

生长方式

贴壁

倍增时间

 大约38~76小时

培养基和添加剂

RPMI-1640(品牌:中乔新舟 货号:ZQ-200)+10%FBS(品牌:中乔新舟 货号:ZQ500-A+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0384

生物安全等级

BSL-1

STR位点信息

Amelogenin: X,Y

CSF1PO: 11,12

D13S317: 8,12

D16S539: 12,13

D5S818: 10,12

D7S820: 10,11

TH01: 6

TPOX: 8,9

vWA: 17

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

 ***

基因表达

 ***

保藏机构

ATCC; CRL-5807 ECACC; 95111733

供应限制

仅供科研使用


货号

ZQ0384

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


论文标题: NEDD4L-induced ubiquitination mediating UBE2T degradation inhibits progression of lung adenocarcinoma via PI3K-AKT signaling
DOI: 10.1186/s12935-021-02341-9
发表时间: 2021-11-27
期刊: Cancer Cell International
影响因子: 5.722
货号: ZQ0384
产品名称: H358 cells

原文链接: https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-02341-9


论文标题: LncRNA PCBP1-AS1 correlated with the functional states of cancer cells and inhibited lung adenocarcinoma metastasis by suppressing the EMT progression
DOI: 10.1093/carcin/bgab047
发表时间: 2021-07-16
期刊: CARCINOGENESIS
影响因子: 4.944
货号: ZQ0384
产品名称: H358 cells
原文链接: https://academic.oup.com/carcin/advance-article-abstract/doi/10.1093/carcin/bgab047/6295508


 论文标题: High expression of 14‑3‑3ơ indicates poor prognosis and progression of lung adenocarcinoma
DOI: 10.3892/ol.2022.13323
发表时间: 2022-05-12
期刊: Oncology Letters
影响因子: 2.967
货号: ZQ0384
产品名称: NCI-H358 cells
原文链接: https://www.spandidos-publications.com/10.3892/ol.2022.13323


论文标题: Loading MicroRNA-376c in Extracellular Vesicles Inhibits Properties of Non-Small Cell Lung Cancer Cells by Targeting YTHDF1:
DOI: 10.1177/1533033820977525
发表时间: 2020-12-07
期刊: TECHNOLOGY IN CANCER RESEARCH & TREATMENT
影响因子: 2.074
货号: ZQ0384
产品名称: NCI-H358 cells

原文链接: https://journals.sagepub.com/doi/abs/10.1177/1533033820977525



PubMed=3940644
Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.
Cancer Res. 46:798-806(1986)


PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)


PubMed=2388294; DOI=10.1093/jnci/82.17.1420
McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C., Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.
Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.
J. Natl. Cancer Inst. 82:1420-1426(1990)


PubMed=2386953
Gazdar A.F., Linnoila R.I., Kurita Y., Oie H.K., Mulshine J.L., Clark J.C., Whitsett J.A.
Peripheral airway cell differentiation in human lung cancer cell lines.
Cancer Res. 50:5481-5487(1990)


PubMed=1311061
Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D., Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Oncogene 7:171-180(1992)


PubMed=1565469
Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D.P., Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F., Linnoila R.I.
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
Oncogene 7:743-749(1992)


PubMed=7972006; DOI=10.1073/pnas.91.23.11045
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)


PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. 63 Suppl. 24:32-91(1996)


PubMed=8806101; DOI=10.1002/jcb.240630514
Lokshin A.E., Levitt M.L.
Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.
J. Cell. Biochem. 63 Suppl. 24:186-197(1996)


PubMed=9649128; DOI=10.1038/bjc.1998.361
Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.
Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.
Br. J. Cancer 77:2162-2170(1998)


PubMed=11030152; DOI=10.1038/sj.onc.1203815
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene 19:4632-4639(2000)


PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0
Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.
Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.
Cancer Genet. Cytogenet. 125:87-99(2001)


PubMed=11464291; DOI=10.1038/sj.onc.1204557
Shigemitsu K., Sekido Y., Usami N., Mori S., Sato M., Horio Y., Hasegawa Y., Bader S.A., Gazdar A.F., Minna J.D., Hida T., Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., Shimokata K.
Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.
Oncogene 20:4249-4257(2001)


PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)


PubMed=18083107; DOI=10.1016/j.cell.2007.11.025
Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P., Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q., Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Cell 131:1190-1203(2007)


PubMed=19472407; DOI=10.1002/humu.21028
Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)


PubMed=24135919; DOI=10.1038/ncomms3617
Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G., Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.
Reconstructing targetable pathways in lung cancer by integrating diverse omics data.
Nat. Commun. 4:2617.1-2617.13(2013)



公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
      上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经十多年发展,...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号